Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in acute lymphoblastic leukemia
- Trial result Spotlight
Acute lymphoblastic leukemia
Ponatinib (BCR-ABL TKI) + blinatumomab (CD19xCD3 BiTE) improves 24-month EFS vs imatinib-chemo in Ph+ ALL
Ponatinib is a third-generation BCR-ABL tyrosine kinase inhibitor and blinatumomab is a CD19xCD3 bispecific T-cell engager; this Phase 3 GIMEMA ALL2820/LAL2820 trial (NCT04722848) randomized frontline adult Ph+ ALL…
NCT04722848 - Trial result Spotlight
Acute lymphoblastic leukemia
Blinatumomab (CD19xCD3 BiTE) Replaces 2 Chemo Blocks and Improves 4-year EFS in Pediatric High-Risk B-ALL
Blinatumomab (Blincyto), a CD19xCD3 bispecific T-cell engager that redirects T cells to kill CD19+ B-lineage blasts, was tested in the randomized Phase 3 AIEOP-BFM ALL 2017 study (EudraCT 2016-001935-12; NCT03643276)…
NCT03643276 - Trial result Spotlight
Acute lymphoblastic leukemia
Everolimus (mTOR inhibitor) + NECTAR salvage delivers 75% ORR in pediatric/AYA R/R T-ALL/T-LL
Everolimus is an oral mTORC1 inhibitor combined here with NECTAR chemotherapy (nelarabine + cyclophosphamide + etoposide) in the multisite ENCERT Phase 1 dose-escalation study in children/young adults with…
NCT03328104 - New trial
Acute lymphoblastic leukemia
Phase 1 BAFFR-CAR T (BAFF-R–targeted CAR-T) in relapsed/refractory B-ALL/B-LL
City of Hope is running a Phase 1, first-in-human study of autologous BAFFR-targeting CAR T cells, an adoptive cell therapy where a patient’s own T cells are genetically engineered to recognize BAFF-R…
NCT07758673 First-in-human - Trial result
Acute lymphoblastic leukemia
MRD ≥0.01% Before or Day 100 Post-HSCT Flags Higher Relapse Risk in Pediatric ALL
Measurable residual disease (MRD) ≥0.01% identified a substantially higher-risk group among 1,014 children and young adults (ages 4–21) receiving matched-donor allogeneic HSCT in the extended international FORUM…
NCT01949129 - Trial result Spotlight
Acute lymphoblastic leukemia
Blinatumomab (CD19×CD3 BiTE) consolidation cuts relapse in high-risk Ph− adult B‑ALL (5‑yr CIR 23% vs 49%)
Blinatumomab is a CD19×CD3 bispecific T‑cell engager given here as an immunotherapy “overlay” on intensive chemotherapy, tested in the Phase 2 GRAALL‑2014/B‑QUEST substudy in newly diagnosed high-risk (KMT2A‑r, IKZF1…
NCT03709719 - Trial result Spotlight
Acute lymphoblastic leukemia
Memory-enriched CD19 CAR-T delivers 84% 18-mo EFS in older CR1 B-ALL
Memory-enriched autologous CD19 CAR-T cells are engineered to target CD19 and were tested as “definitive consolidation” after remission rather than as salvage therapy. In a Phase 1 study in older adults with B-cell…
NCT05707273 - Trial result
Acute lymphoblastic leukemia
Ixazomib (MLN9708) Proteasome Inhibitor + Salvage Chemo Delivers 67% CR in Pediatric R/R ALL
Ixazomib is an oral proteasome inhibitor (more potent than bortezomib preclinically; FDA-approved in multiple myeloma) evaluated in a TACL Phase 1/2, 3+3 dose-escalation study combining ixazomib with established…
NCT03817320 - Trial result
Acute lymphoblastic leukemia
Dose-dense mini–hyper-CVD + inotuzumab (CD22 ADC) + blinatumomab (CD19 BiTE) drives ~95% NGS-MRD negativity in R/R B-ALL, with better 2-year survival when consolidated with CAR-T/SCT
Dose-dense mini–hyper-CVD chemotherapy combined with inotuzumab ozogamicin (anti-CD22 calicheamicin ADC) and blinatumomab (CD19×CD3 bispecific T-cell engager) was evaluated in a Phase 2 study in adults with…
- Trial result
Acute lymphoblastic leukemia
Blinatumomab (CD19 BiTE) + ponatinib (BCR::ABL1 TKI) drives 83% CMR and 89% 3-year OS in frontline Ph+ B-ALL
Blinatumomab is a CD19-directed bispecific T-cell engager (BiTE) paired with ponatinib, a potent BCR::ABL1 tyrosine kinase inhibitor active against T315I, in an ongoing single-arm Phase II frontline study in newly…
NCT03263572 - Trial result
Acute lymphoblastic leukemia
Tisagenlecleucel (CD19 CAR-T) delivers 64% 5-year DFS in frontline MRD+ high-risk pediatric/AYA B-ALL
Tisagenlecleucel (tisa-cel) is an autologous CD19-directed CAR-T therapy tested in the global COG AALL1721/CASSIOPEIA Phase 2 trial (NCT03876769) for very high-risk NCI high-risk B-ALL with persistent MRD ≥0.01% by…
NCT03876769 - Trial result
Acute lymphoblastic leukemia
Olverembatinib (BCR::ABL1 TKI) + blinatumomab (CD19 BiTE) delivers early CR/MRD clearance in heavily pretreated Ph+ ALL/CML-LBP
Olverembatinib (HQP1351) is a third-generation BCR::ABL1 tyrosine kinase inhibitor (active against resistant clones including T315I) combined here with blinatumomab, a CD19×CD3 bispecific T-cell engager, in the Phase…
NCT04260022 - New trial
Acute lymphoblastic leukemia
Phase 1 LP-118 dual BCL-2/BCL-XL inhibitor with ponatinib + blinatumomab in Ph+ ALL
This Phase 1, Wake Forest University Health Sciences–sponsored study tests whether adding LP-118 (an oral small-molecule inhibitor of the anti‑apoptotic proteins BCL-2 and BCL-XL) can be safely combined with a modern…
NCT07614022 Exploratory - New trial
Acute lymphoblastic leukemia
Phase 1 4A10 (ALT-101) tests anti-CD127 (IL-7Rα) blocking antibody in R/R ALL/LL.
Allterum Therapeutics’ first-in-human, open-label Phase 1 study evaluates 4A10, an IgG1 monoclonal antibody that binds CD127 (the IL‑7 receptor alpha chain) to block IL‑7 survival signaling and promote…
NCT07586618 First-in-human - New trial Spotlight
Acute lymphoblastic leukemia
Phase 1 TSLPR-CART anti-TSLPR (CRLF2) CAR T-cell therapy in R/R B-ALL
This first-in-human Phase 1, open-label, 3+3 dose-escalation study sponsored by the National Cancer Institute (NCI) tests autologous TSLPR-CART: a patient’s own T cells engineered to express a chimeric antigen…
NCT07572136 First-in-human - Trial result
Acute lymphoblastic leukemia
Short-course blinatumomab (CD19×CD3 BiTE) clears MRD in B-ALL and gets 90% to transplant in a resource-limited program
Blinatumomab is a CD19×CD3 bispecific T-cell engager (BiTE) given here as a deliberately shortened “MRD-eradication” bridge to allogeneic HCT in CD19+ B-ALL patients in CR with detectable MRD and ≤5% blasts (n=20;…
- Trial result
Acute lymphoblastic leukemia
PAX5-rearranged (PAX5r) B-ALL shows MRD-driven risk: 5-year EFS drops to 44% in high-risk kids
Across consecutive AIEOP-BFM pediatric ALL trials/registries (ALL 2000/2009/2017; 2001-2024), this retrospective series captured 165 children (<18y) with PAX5r BCP-ALL spanning 65 fusion partners (most commonly…
- New trial
Acute lymphoblastic leukemia
Phase 1/1b trial: Venetoclax BCL-2 inhibitor in relapsed B-cell ALL
This study evaluates the safety and effectiveness of combining asparaginase Erwinia chrysanthemi (protein synthesis inhibitor), venetoclax (BCL-2 inhibitor), and blinatumomab (bispecific T-cell engager) in adults…
NCT07133997 Exploratory - New trial
Acute lymphoblastic leukemia
Phase I Asciminib Bcr-Abl Inhibitor Study in Post-Cellular Therapy Ph+ ALL Maintenance
This Phase I trial evaluates asciminib as maintenance therapy for adults with Philadelphia chromosome positive ALL following HSCT or CAR T cell therapy. Patients receive asciminib orally once or twice daily for…
NCT07040982 Exploratory - New trial
Acute lymphoblastic leukemia
Phase 2 Study of Obecabtagene Autoleucel, a CD19-directed CAR-T for High-risk B-cell ALL
This Phase 2 trial at MD Anderson Cancer Center evaluates consolidation therapy with obecabtagene autoleucel, a CD19-directed CAR-T, in patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia…
NCT07053059 Exploratory - Trial result Spotlight
Acute lymphoblastic leukemia
Fresh CD19 CAR T Achieves 100% MRD-Neg CR, 83% 3-yr OS in r/r Pediatric B-ALL
A point-of-care, second-generation 4-1BB CD19 CAR T product was manufactured fresh in 12 days and infused in the Phase I/II NCT04787263 trial (n = 19) enrolling children/young adults in very-high-risk first relapse…
NCT04787263 - Trial result
Acute lymphoblastic leukemia
Blinatumomab (CD19 BiTE) sees 28% attrition after toxic UK ALLR3 re‑induction in relapsed B‑ALL
Blinatumomab, a CD19‑directed bispecific T‑cell engager, was evaluated as post‑induction or salvage therapy in the Children’s Oncology Group Phase 3 AALL1331 trial (NCT02101853), which began with a UK ALLR3-inspired…
NCT02101853 - Trial result Spotlight
Acute lymphoblastic leukemia
Subcutaneous Blinatumomab Achieves 77% CR in Relapsed/Refractory B-ALL, Surpassing IV Benchmarks
Blinatumomab, a CD19×CD3 bispecific T-cell engager, was reformulated for subcutaneous (SC) delivery and evaluated in the phase 1/2 NCT04521231 study across 88 adults with relapsed/refractory B-cell ALL. Once-daily…
NCT04521231 - New trial
Acute lymphoblastic leukemia
Phase 1 CD5.CAR/28zeta CAR-T: engineered T cells targeting CD5 in T-cell malignancies
This trial investigates the safety and persistence of autologous or allogeneic CD5.CAR/28zeta T cells in patients with relapsed or refractory T-cell non-Hodgkin lymphoma and acute lymphocytic leukemia. Conducted by…
NCT03081910 First-in-human - New trial
Acute lymphoblastic leukemia
Phase 3 trial: Imatinib mesylate, a Bcr-Abl/c-KIT/PDGF inhibitor, in Ph+ ALL.
Children’s Oncology Group is evaluating imatinib mesylate with varied chemotherapy regimens—with or without stem cell transplant—to treat newly diagnosed Philadelphia chromosome–positive and ABL-class fusion positive…
NCT03007147 - Trial result
Acute lymphoblastic leukemia
High Baseline WBC Identifies High-Risk Patients in Ph+ ALL on Chemo-Free Regimen
In this phase II trial investigating frontline ponatinib and blinatumomab in 76 Ph+ ALL patients, a 3-year event-free survival of 78% and overall survival of 88% were observed, with 13% of patients relapsing—most…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.